
GABA A receptor agonist - Pipeline Insight, 2025
Description
DelveInsight’s, “GABA A receptor agonist - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in GABA A receptor agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
GABA A receptor agonist: Overview
Type-A γ-aminobutyric acid receptors (GABAARs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABAAR signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. GABAARs are the targets of a wide range of drugs including benzodiazepines, used in the treatment of epilepsy, insomnia, anxiety and panic disorder, and the intravenous general anaesthetics propofol and etomidate. GABAARs also mediate alcohol inebriation and are targets for endogenous modulators such as neurosteroids.
Report Highlights
This segment of the GABA A receptor agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA A receptor agonist Emerging Drugs
Further product details are provided in the report……..
GABA A receptor agonist: Therapeutic Assessment
This segment of the report provides insights about the different GABA A receptor agonist drugs segregated based on following parameters that define the scope of the report, such as:
GABA A receptor agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses GABA A receptor agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA A receptor agonist drugs.
GABA A receptor agonist Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
GABA A receptor agonist: Overview
Type-A γ-aminobutyric acid receptors (GABAARs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABAAR signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. GABAARs are the targets of a wide range of drugs including benzodiazepines, used in the treatment of epilepsy, insomnia, anxiety and panic disorder, and the intravenous general anaesthetics propofol and etomidate. GABAARs also mediate alcohol inebriation and are targets for endogenous modulators such as neurosteroids.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence GABA A receptor agonist R&D. The therapies under development are focused on novel approaches for GABA A receptor agonist.
This segment of the GABA A receptor agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA A receptor agonist Emerging Drugs
- Ganaxolone: Marinus Pharmaceuticals
- Padsevonil: UCB Biopharma
Further product details are provided in the report……..
GABA A receptor agonist: Therapeutic Assessment
This segment of the report provides insights about the different GABA A receptor agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on GABA A receptor agonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
GABA A receptor agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses GABA A receptor agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA A receptor agonist drugs.
GABA A receptor agonist Report Insights
- GABA A receptor agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing GABA A receptor agonist drugs?
- How many GABA A receptor agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for GABA A receptor agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GABA A receptor agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for GABA A receptor agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Marinus Pharmaceuticals
- UCB Biopharma
- Confluence Pharmaceuticals
- Cerevel Therapeutics
- Sichuan Haisco Pharmaceutical
- Ovid Therapeutics
- Ganaxolone
- Padsevonil
- Acamprosate
- Darigabat
- Ciprofol
- OV101
Table of Contents
60 Pages
- Introduction
- Executive Summary
- GABA A receptor agonist: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- GABA A receptor agonist – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- GABA A receptor agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- GABA A receptor agonist Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Ganaxolone: Marinus Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- Comparative Analysis
- Padsevonil: UCB Biopharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Darigabat: Cerevel Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- GABA A receptor agonist Key Companies
- GABA A receptor agonist Key Products
- GABA A receptor agonist- Unmet Needs
- GABA A receptor agonist- Market Drivers and Barriers
- GABA A receptor agonist- Future Perspectives and Conclusion
- GABA A receptor agonist Analyst Views
- GABA A receptor agonist Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.